With ASCO coming, it takes guts to short this aggressively.
I've long considered it likely that 607 would cannibalize 67. And there's the usual stuff..... lead molecules fail at high rate, toxic stuff, etc. Other than that, I know of no weakness.
So..... the knocks:
CMV is a small market. Anti-folate? BFD. 67 better than 607? Everything else is preclinical. High burn. Big research premium.
The positives:
If 67 works, it's very big news, and 607 might then be monstrous. CMV market, unfortunately, will start to grow. Existing therapies are ineffective and/or toxic. Preclinical pipeline is loaded.
I've only been a shareholder for about eight months. I don't have a trading position, just a small "gonna hold" position. I like it, and -- if the shorts have a case and there's bad news coming -- I may then load a boat.
In any event..... yesterday, Son of Imclone....... today, Sepracor. |
